Terutroban

Terutroban_acid_skeletal.svg

Terutroban is a pharmaceutical drug that acts as a selective thromboxane receptor antagonist. It is primarily investigated for its potential use in the treatment of cardiovascular diseases, particularly in the prevention of atherothrombosis.

Mechanism of Action

Terutroban works by inhibiting the action of thromboxane A2, a compound that promotes platelet aggregation and vasoconstriction. By blocking the thromboxane receptor, Terutroban reduces the risk of blood clot formation and helps to maintain proper blood flow in the arteries.

Clinical Uses

Terutroban has been studied for its effectiveness in preventing strokes and other cardiovascular events in patients with a history of transient ischemic attacks (TIAs) or ischemic strokes. It is also being explored as a potential treatment for peripheral artery disease and other conditions characterized by impaired blood flow.

Research and Development

The development of Terutroban has involved numerous clinical trials to assess its safety and efficacy. These studies have compared Terutroban to other antiplatelet agents, such as aspirin, to determine its relative benefits and risks.

Side Effects

Common side effects of Terutroban may include headache, dizziness, and gastrointestinal disturbances. As with other antiplatelet drugs, there is a risk of bleeding complications, which must be carefully monitored.

See Also

• Thromboxane
• Platelet aggregation
• Cardiovascular disease
• Atherothrombosis
• Antiplatelet drug

External Links

-

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian